The current state of adverse event reporting in hemophilia

References

• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544.
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. The impact of HIV on mortality rates in the complete UK haemophilia population. Aids. 2004;18:525–533.
   PubMed Web of Science ®Google Scholar
• Makris M, Garson JA, Ring CJ, et al. Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood. 1993;81:1898–1902.
   PubMed Web of Science ®Google Scholar
• Shin HR, Kim JY, Kim JI, et al. Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture. Br J Cancer. 2002;87:314–318.
   PubMed Web of Science ®Google Scholar
• Garson JA, Preston FE, Makris M, et al. Detection by PCR of hepatitis C virus in factor VIII concentrates. Lancet. 1990;335:1473.
   PubMed Web of Science ®Google Scholar
• Van De Putte DEF, Makris M, Fischer K, et al. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol. 2014;60::39–45.
   PubMedGoogle Scholar
• Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14:671–684.
   PubMed Web of Science ®Google Scholar
• Meeks SL, Josephson CD. Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates. Curr Opin Hematol. 2006;13:457–461.
   PubMed Web of Science ®Google Scholar
• Lassila R, Makris M. Safety surveillance in haemophilia and allied disorders. J Intern Med. 2016;279:515–523.
   PubMed Web of Science ®Google Scholar
• DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13(Suppl 1):1–22.
   PubMed Web of Science ®Google Scholar
• Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood. 2012;120:720–727.
   PubMed Web of Science ®Google Scholar
• Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophiliathe. 2006;12(Suppl 6):8–13; discussion −4.
   Google Scholar
• Astermark J. FVIII inhibitors: pathogenesis and avoidance. Blood. 2015;125:2045–2051.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. Trial of factor viii and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–2064.
   PubMed Web of Science ®Google Scholar
• Tabriznia-Tabrizi S, Gholampour M, Mansouritorghabeh H. A close insight to factor VIII inhibitor in the congenital hemophilia A. Expert Rev Hematol. 2016;9:903–913.
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418–435.
   PubMed Web of Science ®Google Scholar
• Franchini M, Tagliaferri A, Mengoli C, et al. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol. 2012;81:82–93.
   PubMed Web of Science ®Google Scholar
• Gouw SC, Van Der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368:231–239.
   PubMed Web of Science ®Google Scholar
• Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Thromb Haemost. 2010;8:1256–1265.
   Web of Science ®Google Scholar
• Calvez T, Chambost H, Claeyssens-Donadel S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124:3398–3408.
   PubMed Web of Science ®Google Scholar
• Collins PW, Palmer BP, Chalmers EA, et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood. 2014;124:3389–3397.
   PubMed Web of Science ®Google Scholar
• Fischer K, Iorio A, Hollingsworth R, et al. FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. Haemophilia. 2016;22:e36–8.
   PubMed Web of Science ®Google Scholar
• Fischer K, Lassila R, Peyvandi F, et al. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost. 2015;113:968–975.
   PubMed Web of Science ®Google Scholar
• EMA. Inhibitor development in previously untreated patients with severe haemophilia A treated with recombinant factor VIII products. www.ema.europa.eu/docs/en_GB/document_library/Report/2016/05/WC500206411.pdf2016.
   Google Scholar
• Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. Thromb Haemost. 2011;9:2180–2192.
   Web of Science ®Google Scholar
• Xi M, Makris M, Marcucci M, et al. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. Thromb Haemost. 2013;11:1655–1662.
   Web of Science ®Google Scholar
• Rosendaal FR, Briet E, Stibbe J, et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol. 1990;75:525–530.
   PubMed Web of Science ®Google Scholar
• Makris M, Van Veen JJ. Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic load. Thromb Haemost. 2012;10:20–22.
   Web of Science ®Google Scholar
• Coppola A, Franchini M, Makris M, et al. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia. 2012;18:e173–87.
   PubMed Web of Science ®Google Scholar
• Girolami A, Scandellari R, Zanon E, et al. Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases. J Thromb Thrombolysis. 2006;21:279–284.
   PubMed Web of Science ®Google Scholar
• Blatny J, Mathew P, Monagle P, et al. Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry. Blood Coagulation & Fibrinolysis. 2014;25:326–332.
   PubMed Web of Science ®Google Scholar
• Mauser-Bunschoten EP, Fransen Van De Putte DE, Schutgens RE. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia. 2009;15:853–863.
   PubMed Web of Science ®Google Scholar
• Franchini M, Makris M, Santagostino E, et al. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand’s disease: a systematic review of prospective studies. Haemophilia. 2012;18:e164–72.
   PubMed Web of Science ®Google Scholar
• Chitlur M, Warrier I, Rajpurkar M, et al. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia. 2009;15:1027–1031.
   PubMed Web of Science ®Google Scholar
• Keipert C, Van Den Berg HM, Keller-Stanislawski B, et al. Haemophilia registries to complement clinical trial data: a pious hope or an urgent necessity?: reflections on a possible way forward. Haemophilia. 2016;22:647–650.
   PubMed Web of Science ®Google Scholar
• Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011;117:6367–6370.
   PubMed Web of Science ®Google Scholar
• Maclean PS, Richards M, Williams M, et al. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia. 2011;17:282–287.
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815–825.
   PubMed Web of Science ®Google Scholar
• Hay CR, Palmer BP, Chalmers EA, et al. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison. Haemophilia. 2015;21:219–226.
   PubMed Web of Science ®Google Scholar
• Soucie JM, Miller CH, Kelly FM, et al. A public health approach to the prevention of inhibitors in hemophilia. Am J Prev Med. 2014;47:669–673.
   PubMed Web of Science ®Google Scholar
• Soucie JM, Miller CH, Kelly FM, et al. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 2014;20:230–237.
   PubMed Web of Science ®Google Scholar
• Puetz J, Soucie JM, Kempton CL, et al. Prevalent inhibitors in haemophilia B subjects enrolled in the universal data collection database. Haemophilia. 2014;20:25–31.
   PubMed Web of Science ®Google Scholar
• Van Der Bom JG, Gouw SC, Rosendaal FR. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A. Haemophilia. 2014;20:e171–4.
   Google Scholar
• Gouw SC, Van Den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121:4046–4055.
   PubMed Web of Science ®Google Scholar
• Clausen N, Petrini P, Claeyssens-Donadel S, et al. Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia. 2014;20:747–755.
   PubMed Web of Science ®Google Scholar
• Makris M, Calizzani G, Fischer K, et al. EUHASS: the european haemophilia safety surveillance system. Thromb Res. 2011;127(Suppl 2):S22–5.
   PubMed Web of Science ®Google Scholar
• Fischer K, Iorio A, Lassila R, et al. Inhibitor development in non-severe haemophilia across Europe. Thromb Haemost. 2015;114:670–675.
   PubMed Web of Science ®Google Scholar
• Blatny J, Komrska V, Blazek B, et al. Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003. Blood Coagulation & Fibrinolysis. 2015;26:673–678.
   PubMed Web of Science ®Google Scholar
• Soucie JM, De Staercke C, Monahan PE, et al. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion. 2013;53:1217–1225.
   PubMed Web of Science ®Google Scholar
• O’Riordan J, Boland F, Williams P, et al. Hepatitis E virus infection in the Irish blood donor population. Transfusion. 2016. doi:10.1111/trf.13757. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Shrestha AC, Flower RL, Seed CR, et al. Hepatitis E virus infections in travellers: assessing the threat to the Australian blood supply. Blood Transfus. 2016;1–8. doi:10.2450/2016.0064-16. [Epub ahead of print].
   PubMedGoogle Scholar
• Wang M, Fu P, Yin Y, et al. Recent and past hev infection among voluntary blood donors in china: a systematic review and meta-analysis. Plos One. 2016;11:e0161089.
   Google Scholar
• Farcet MR, Lackner C, Antoine G, et al. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes. Transfusion. 2016;56:383–391.
   PubMed Web of Science ®Google Scholar
• The Proceedings of the World Federation of Hemophilia’s Ninth Global Forum on Research and Treatment Products for Bleeding Disorders. Montreal: Canada. Place; World Federation of Hemophilia. 2015.
   Google Scholar
• Peyvandi F, Garagiola I, Biguzzi E. Advances in treatment of bleeding disorders. Thromb Haemost. 2016;14:2095–2106.
   Google Scholar
• Hartmann J, Croteau SE. Clinical Trials Update: Innovations in Hemophilia Therapy. Am J Hematol. 2016;91:1252–1260.
   PubMedGoogle Scholar
• Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22:487–498.
   PubMed Web of Science ®Google Scholar
• Ing M, Gupta N, Teyssandier M, et al. Immunogenicity of long-lasting recombinant factor VIII products. Cell Immunol. 2016;301:40–48.
   PubMed Web of Science ®Google Scholar
• Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319–1323.
   PubMed Web of Science ®Google Scholar
• Verhoef JJ, Carpenter JF, Anchordoquy TJ, et al. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today. 2014;19:1945–1952.
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110:103–111.
   PubMed Web of Science ®Google Scholar
• Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127:1633–1641.
   PubMed Web of Science ®Google Scholar
• Shima M, Lillicrap D, Kruse-Jarres R. Alternative therapies for the management of inhibitors. Haemophilia. 2016;22(Suppl 5):36–41.
   PubMed Web of Science ®Google Scholar
• Peterson JA, Maroney SA, Mast AE. Targeting TFPI for hemophilia treatment. Thromb Res. 2016;141(Suppl 2):S28–30.
   Google Scholar
• Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13:743–754.
   PubMed Web of Science ®Google Scholar
• Hilden I, Lauritzen B, Sorensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119:5871–5878.
   PubMed Web of Science ®Google Scholar
• Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21:492–497.
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994–2004.
   PubMed Web of Science ®Google Scholar
• Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361:1671–1675.
   PubMed Web of Science ®Google Scholar
• George LA, Sullivan S, Teitel J, et al. Preliminary results of a phase 1/2 trial of SPK-9001, a hyperactive FIX variant delivered by a novel capsid, demonstrate consistent factor IX activity levels at the lowest dose cohort. Haemophilia. 2016;22:151.
   Web of Science ®Google Scholar
• Heijnen L, De Kleijn P. Physiotherapy for the treatment of articular contractures in haemophilia. Haemophilia. 1999;5(Suppl 1):16–19.
   PubMed Web of Science ®Google Scholar
• Pasi J, Wong W, Rangarajan S, et al. Interim results of an open-label, phase 1/2 study of BMN 270, an AAV5-FVIII gene transfer in severe hemophilia A. Haemophilia. 2016;22:151.
   Google Scholar
• Al-Haddad MA, Friedlin J, Kesterson J, et al. Natural language processing for the development of a clinical registry: a validation study in intraductal papillary mucinous neoplasms. Hpb. 2010;12:688–695.
   PubMed Web of Science ®Google Scholar